Category: Portfolio News
Ventyx Biosciences announces positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in patients with early-stage Parkinson’s disease
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, the “Company”), a clinical-stage biotech company developing oral therapies for autoimmune, inflammatory and neurodegenerative diseases, has announced positive top-line results from its Phase 2a study of VTX3232, a novel, CNS-penetrant NLRP3 inhibitor, in patients with early-stage Parkinson’s disease (NCT06556173). The study accomplished the primary
Read More
Resolve Therapeutics and Duke Medical School initiate observational study of cell-free RNA in polytrauma patients
Resolve Therapeutics, a leader in the emerging field of cell-free nucleic acid therapeutics, has announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma. A significant number of trauma patients admitted to the hospital each year suffer
Read More
Achronix announces new VectorPath 815 FPGA Accelerator Card
Achronix Semiconductor Corporation, the leader in data acceleration FPGAs, has announced the launch of the VectorPath® 815 (VP815), a new PCIe accelerator card powered by the industry- leading Speedster® 7t1500 FPGA, and engineered to meet the growing demands of AI workloads and high-performance computing (HPC). FPGAs are uniquely suited for
Read More
Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the five-year follow-up results from the Phase 1/2 clinical trial of its investigational tissue regeneration product, NVD003, in adult patients with severe bone non-union (BNU) of the lower limb, following trauma. The five-year safety and efficacy data
Read More
VUV Analytics introduces HYDRA™: A breakthrough Vacuum Ultraviolet Detector for Liquid Chromatography
VUV Analytics, Inc., a global leader in vacuum ultraviolet (VUV) spectroscopy, is excited to introduce HYDRA, a breakthrough detector for Liquid Chromatography (LC). HYDRA makes advanced chemical analysis easier with universal detection, exceptional spectral selectivity, and seamless integration into lab workflows. “HYDRA is a major step forward for Liquid Chromatography
Read MoreNovadip appoints Soumya Chandramouli as Chief Financial Officer
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the appointment of Soumya Chandramouli as Chief Financial Officer (CFO). Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare
Read More
San José City Council unanimously approves next phase of San José Airport Connector Project
San José Connection Partners, a consortium including Plenary Americas, Webcor/Obayashi, and HNTB, and Glydways has announced that the San José City Council voted unanimously to move the Diridon–Airport Connector into Phase 2a of project development. The decision marks a significant step toward achieving the City’s sustainable mobility goals, reflecting strong
Read More
NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, has announced that results from the Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 metabolic dysfunction-associated steatohepatitis (MASH) were published in the Journal of Hepatology.
Read MoreVentyx Biosciences announces presentation of data from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in Crohn’s Disease at ECCO 2025
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn’s disease will be presented during the 20th Congress of
Read More
RANsemi partners with Antevia Networks to provide silicon for Open RAN Radio Units
RANsemi, a British wireless semiconductor innovator specialising in 5G Open RAN baseband technologies, has partnered with Antevia Networks for its 5G SHIFT enterprise private 5G platform. 5G SHIFT employs Open RAN (O-RAN) fronthaul technology in its Radio Units (O-RUs) running on RANsemi 5G PHY SoCs to enhance in-building wireless coverage.
Read MoreVentyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. “We believe that 2025 will be
Read More
Phase Four Series C first closing
Phase Four, a leader in advanced in-space propulsion design and manufacturing, has announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. The round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed
Read More